Oncology
Conditions
Brief summary
The investigators are developing a novel standardized and centralized approach named Integrated Personalized Functional Profiling (PFP) in Luxembourg. Based on recent improvements in cancer biopsy-derived 3D-culture technologies the PFP process will screen patient derived cells (PDCs) with FDA/EMA-approved drugs to generate personalized functional response profiles. The selected drug through PFP technology will provide personalized treatment recommendation for the patient. This pilot study will evaluate the clinical feasibility of setting-up an effective workflow as a first step. Outcomes from this study will be used subsequently to help plan the clinical validation of the implementation of PFP.
Interventions
DIAGNOSTIC_TESTPersonalized Functional Profiling
During this pilot study, the overall goal of the project is to establish an effective workflow between the patient, the PFP platform, the clinician and return to the patient. This includes collection of the biopsy or surgery piece and standardized processing, dissociation, drug profiling and issuing treatment recommendation to the clinician. In case the clinician follows this treatment recommendation, patient management and follow up will be performed according to standard of care.
Sponsors
Integrated Biobank of Luxembourg
Laboratoire National de Santé (Luxembourg)
Centre Hospitalier du Luxembourg
Hopitaux Robert Schuman (Luxembourg)
Luxembourg Institute of Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with recurrent Glioblastoma (rGBM) or with metastatic gastrointestinal cancer (mGIC), i.e. adenocarcinoma (any grade) of stomach, liver, pancreas, small intestine, colon, rectum * The patient has received previous cancer treatment for mGIC or rGBM * Male or female ≥ 18 years * Life expectancy ≥ 12 weeks * Histologically or cytologically confirmed diagnosis for mGIC or recurrence of a glioblastoma, WHO grade IV * For women of childbearing potential, a negative pregnancy test documented prior to the screening visit is required * Signed Inform Consent Form before any study related procedure
Exclusion criteria
* For female patient, being pregnant, planning a pregnancy or breastfeeding * No fresh and viable tumor material available * Known active Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection * Uncontrolled medical conditions (i.e, diabetes mellitus, hypertension, etc), psychological, familial, sociological, or geographical conditions that do not allow compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol * In mGIC arm, patient with non-adenocarcinoma gastrointestinal cancer * Patient unable to understand and consent himself
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients for which a treatment recommendation for their specific cancer can be formulated, based on PFP | 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Quantity of cells needed for the PFP analysis | 4 weeks |
| Duration of the PFP process for one specific patient | 4 weeks |
| Number of drugs recommended by using the PFP approach | 4 weeks |
| Number of patients for which the treatment recommendation issued by PFP were followed by the investigator | 4 weeks |
Countries
Luxembourg
Outcome results
None listed